Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $89,131.98 in Stock

Posted by Joseph Casey on Nov 18th, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 90,951 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $0.98, for a total value of $89,131.98. Following the completion of the sale, the insider directly owned 5,600,240 shares of the company’s stock, valued at $5,488,235.20. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total transaction of $54,207.95.
On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $57,325.20.
On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $63,623.40.
On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $57,312.60.
On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80.
On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.

Werewolf Therapeutics Trading Up 0.1%

Shares of NASDAQ:HOWL traded up $0.00 during midday trading on Monday, reaching $0.92. 519,418 shares of the company’s stock were exchanged, compared to its average volume of 503,244. The stock has a market cap of $44.63 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.38. The firm’s 50 day simple moving average is $1.57 and its two-hundred day simple moving average is $1.34. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on HOWL shares. Bank of America lowered their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 25th. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, JMP Securities dropped their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Read Our Latest Analysis on HOWL

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP lifted its stake in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the last quarter. MPM Bioimpact LLC increased its position in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC lifted its position in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $28,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.